Jan. 13, 2026

Dr. Chai Yan Joins Qurgen/Fuent as Senior Vice President for BP，Qurgen, CEO，Suzhou Fuent Pharmaceutics and Board Secretary of Both Qurgen and Suzhou Fuent Pharmaceutics.

• On January 13, 2026, Dr. Chai Yan officially joined Qurgen/Fuent, assuming the positions of Senior Vice President in charge of BP, Qurgen, Chief Executive Officer (CEO) of Suzhou Fuent Pharmaceutics, and Board Secretary of both Qurgen and Suzhou Fuent Pharmaceutics.  
• As the company enters the clinical stage, it requires not only scientific breakthroughs in pioneering new technologies, but also strategic upgrade and robust execution. Dr. Chai will lead Qurgen and Suzhou Fuent for continuous strategic upgrades and execution. In particular, Dr. Chai will oversee business expansion and development, fund-raising and financing management, and overall operations of Suzhou Fuent. Dr. Chai’s extensive expertise in corporate management and capital operations will provide strong leadership in the company’s continuous strategic upgrade and business expansion as well as strongly support the company to achieve key milestones.  
• Prior to joining Qurgen/Fuent, Dr. Chai served as the Chief Operating Officer   at IQVIA, where he led commercial consulting, contracted commercial services, market access & public policy advocacy and government affairs. Earlier in his career, he held analytical and investment roles at McKinsey & Company and the Harvard Management Company.  
• Dr. Chai Yan holds a Master degree in International Management from the University of Nottingham (UK) and a Doctor of Business Administration (DBA) with a concentration in Finance from Arizona State University (USA).  
• “I am honored to join Qurgen/FuentFuent at this critical stage of development,”  Dr. Chai Yan continues, “Qurgen/Fuent boasts a solid scientific foundation, a clear clinical roadmap, and a highly competitive R&D and manufacturing team. Going forward, we will not only validate the value of functional protein therapeutics scientifically but also fully demonstrate the company’s potential in the capital markets. I will work closely with the management team to advance corporate development, enhance operational efficiency, ensure precise resource allocation to high-value pipelines, and deliver innovative treatment solutions to patients at an early date.”